Notice: This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends TROV vs. INMB, CLLS, IPSC, SCLX, HLVX, CABA, QNCX, GNTA, IVVD, and IKNAShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include INmune Bio (INMB), Cellectis (CLLS), Century Therapeutics (IPSC), Scilex (SCLX), HilleVax (HLVX), Cabaletta Bio (CABA), Quince Therapeutics (QNCX), Genenta Science (GNTA), Invivyd (IVVD), and Ikena Oncology (IKNA). These companies are all part of the "medical" sector. Cardiff Oncology vs. INmune Bio Cellectis Century Therapeutics Scilex HilleVax Cabaletta Bio Quince Therapeutics Genenta Science Invivyd Ikena Oncology Cardiff Oncology (NASDAQ:TROV) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings. Do analysts rate TROV or INMB? INmune Bio has a consensus target price of $20.00, indicating a potential upside of 310.68%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts clearly believe INmune Bio is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00INmune Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, TROV or INMB? Cardiff Oncology has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$250K107.91-$16.41M-$2.80-0.88INmune Bio$42K2,570.90-$30.01M-$2.18-2.23 Does the media favor TROV or INMB? In the previous week, Cardiff Oncology's average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score. Company Overall Sentiment Cardiff Oncology Neutral INmune Bio Neutral Which has more volatility and risk, TROV or INMB? Cardiff Oncology has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Do institutionals and insiders hold more shares of TROV or INMB? 10.0% of Cardiff Oncology shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 0.6% of Cardiff Oncology shares are held by company insiders. Comparatively, 35.2% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer TROV or INMB? Cardiff Oncology received 262 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.09% of users gave INmune Bio an outperform vote while only 73.09% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformCardiff OncologyOutperform Votes40273.09% Underperform Votes14826.91% INmune BioOutperform Votes14076.09% Underperform Votes4423.91% Is TROV or INMB more profitable? Cardiff Oncology has a net margin of -3,688.31% compared to INmune Bio's net margin of -26,333.59%. INmune Bio's return on equity of -117.48% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-3,688.31% -202.00% -122.92% INmune Bio -26,333.59%-117.48%-78.96% SummaryINmune Bio beats Cardiff Oncology on 11 of the 16 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.98M$3.03B$5.21B$8.85BDividend YieldN/A1.86%5.53%4.08%P/E Ratio-0.8125.0782.8815.55Price / Sales107.91298.431,246.7687.28Price / CashN/A172.5640.9136.92Price / Book2.614.607.206.55Net Income-$16.41M-$41.63M$119.63M$226.22M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$2.45-2.0%N/A+117.4%$26.98M$250,000.00-0.81N/AINMBINmune Bio1.7699 of 5 stars$4.87+2.3%$20.00+310.7%-43.6%$107.97M$160,000.00-2.2310CLLSCellectis2.8759 of 5 stars$1.87+0.5%$7.00+274.3%-33.3%$103.94M$29.07M-1.44290Analyst ForecastIPSCCentury Therapeutics1.5736 of 5 stars$1.21-2.4%$11.60+858.7%-21.9%$102.89M$2.23M-0.67170SCLXScilex3.2689 of 5 stars$0.52-5.6%$11.33+2,076.1%-48.4%$99.88M$46.74M-0.3980High Trading VolumeHLVXHilleVax3.3794 of 5 stars$1.86+2.2%$3.00+61.3%-86.5%$92.65MN/A-0.5990Positive NewsCABACabaletta Bio2.0471 of 5 stars$1.87flat$27.30+1,359.9%-89.9%$91.41MN/A-0.8750Gap UpHigh Trading VolumeQNCXQuince Therapeutics2.6718 of 5 stars$1.96-5.8%$8.50+333.7%+116.3%$86.24MN/A-1.6860Positive NewsGap UpHigh Trading VolumeGNTAGenenta Science2.2319 of 5 stars$4.69-2.3%$25.00+433.0%-6.6%$85.78MN/A0.007News CoverageGap UpIVVDInvivyd2.1628 of 5 stars$0.70+0.2%$7.52+971.7%-53.2%$83.90MN/A-0.36100Analyst ForecastAnalyst RevisionNews CoverageGap UpIKNAIkena Oncology3.1944 of 5 stars$1.71-1.2%$3.00+75.4%+4.9%$82.53M$9.16M-1.4170 Related Companies and Tools Related Companies INMB Competitors CLLS Competitors IPSC Competitors SCLX Competitors HLVX Competitors CABA Competitors QNCX Competitors GNTA Competitors IVVD Competitors IKNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TROV) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
